Adaptive Biotechnologies Corp Stock Analysis

ADPT Stock  USD 8.24  0.18  2.14%   
Adaptive Biotechnologies Corp is fairly valued with Real Value of 8.33 and Target Price of 7.58. The main objective of Adaptive Biotechnologies stock analysis is to determine its intrinsic value, which is an estimate of what Adaptive Biotechnologies Corp is worth, separate from its market price. There are two main types of Adaptive Biotechnologies' stock analysis: fundamental analysis and technical analysis.
The Adaptive Biotechnologies stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Adaptive Biotechnologies is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Adaptive Stock trading window is adjusted to America/New York timezone.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adaptive Biotechnologies Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

Adaptive Stock Analysis Notes

About 94.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 1.08. Adaptive Biotechnologies had not issued any dividends in recent years. Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington. Adaptive Biotechnologies operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 858 people. For more info on Adaptive Biotechnologies Corp please contact Chad MBA at 206 659 0067 or go to https://www.adaptivebiotech.com.

Adaptive Biotechnologies Quarterly Total Revenue

47.46 Million

Adaptive Biotechnologies Investment Alerts

Adaptive Biotechnologies is way too risky over 90 days horizon
Adaptive Biotechnologies appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 178.96 M. Net Loss for the year was (159.59 M) with profit before overhead, payroll, taxes, and interest of 89.8 M.
Adaptive Biotechnologies Corp currently holds about 383.74 M in cash with (95.21 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.69.
Over 94.0% of the company shares are held by institutions such as insurance companies
Latest headline from news.google.com: Adaptive Biotechnologies chief scientific officer sells shares for 15,282 - Investing.com

Adaptive Biotechnologies Upcoming and Recent Events

13th of February 2024
Upcoming Quarterly Report
View
1st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
13th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Adaptive Largest EPS Surprises

Earnings surprises can significantly impact Adaptive Biotechnologies' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2020-02-26
2019-12-31-0.2-0.170.0315 
2021-02-24
2020-12-31-0.29-0.33-0.0413 
2020-05-12
2020-03-31-0.2-0.25-0.0525 
View All Earnings Estimates

Adaptive Biotechnologies Environmental, Social, and Governance (ESG) Scores

Adaptive Biotechnologies' ESG score is a quantitative measure that evaluates Adaptive Biotechnologies' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Adaptive Biotechnologies' operations that may have significant financial implications and affect Adaptive Biotechnologies' stock price as well as guide investors towards more socially responsible investments.

Adaptive Stock Institutional Investors

Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
State Street Corp2024-12-31
2.7 M
Geode Capital Management, Llc2024-12-31
2.7 M
Ing Investment Management Llc2024-12-31
2.4 M
Goldman Sachs Group Inc2024-12-31
2.2 M
Blue Water Life Science Advisors, Llc2024-12-31
2.1 M
Dimensional Fund Advisors, Inc.2024-12-31
1.6 M
Pier Capital, Llc2024-12-31
1.3 M
Morgan Stanley - Brokerage Accounts2024-12-31
1.2 M
Northern Trust Corp2024-12-31
1.1 M
Viking Global Investors Lp2024-12-31
30 M
Rubric Capital Management Lp2024-12-31
14.6 M
Note, although Adaptive Biotechnologies' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Adaptive Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.22 B.

Adaptive Profitablity

The company has Profit Margin (PM) of (0.89) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.71) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.71.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.38)(0.40)
Return On Capital Employed(0.37)(0.39)
Return On Assets(0.30)(0.31)
Return On Equity(0.79)(0.75)

Management Efficiency

Adaptive Biotechnologies has return on total asset (ROA) of (0.1617) % which means that it has lost $0.1617 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6249) %, meaning that it created substantial loss on money invested by shareholders. Adaptive Biotechnologies' management efficiency ratios could be used to measure how well Adaptive Biotechnologies manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.4 in 2025. Return On Capital Employed is likely to drop to -0.39 in 2025. At this time, Adaptive Biotechnologies' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 265.7 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 87.6 M in 2025.
Last ReportedProjected for Next Year
Book Value Per Share 1.38  2.04 
Tangible Book Value Per Share 0.54  0.52 
Enterprise Value Over EBITDA(7.18)(7.54)
Price Book Value Ratio 4.35  4.57 
Enterprise Value Multiple(7.18)(7.54)
Price Fair Value 4.35  4.57 
Enterprise ValueB952.5 M
Effective leadership at Adaptive Biotechnologies drives its competitive edge in the market. Our analysis focuses on how this translates to financial performance and stock value.
Operating Margin
(0.71)
Profit Margin
(0.89)
Beta
1.532
Return On Assets
(0.16)
Return On Equity
(0.62)

Technical Drivers

As of the 27th of March, Adaptive Biotechnologies shows the risk adjusted performance of 0.1101, and Mean Deviation of 3.54. Adaptive Biotechnologies technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

Adaptive Biotechnologies Price Movement Analysis

Execute Study
The output start index for this execution was thirteen with a total number of output elements of fourty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Adaptive Biotechnologies middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Adaptive Biotechnologies. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Adaptive Biotechnologies Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Adaptive Biotechnologies insiders, such as employees or executives, is commonly permitted as long as it does not rely on Adaptive Biotechnologies' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Adaptive Biotechnologies insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Griffin Michelle Renee over a week ago
Disposition of 36291 shares by Griffin Michelle Renee of Adaptive Biotechnologies at 7.19 subject to Rule 16b-3
 
Kyle Piskel over a week ago
Disposition of 2500 shares by Kyle Piskel of Adaptive Biotechnologies at 6.32 subject to Rule 16b-3
 
Griffin Michelle Renee over a week ago
Disposition of 36291 shares by Griffin Michelle Renee of Adaptive Biotechnologies at 7.19 subject to Rule 16b-3
 
Hershberg Robert over two weeks ago
Disposition of 53000 shares by Hershberg Robert of Adaptive Biotechnologies at 7.59 subject to Rule 16b-3
 
Neupert Peter M over two weeks ago
Disposition of 50000 shares by Neupert Peter M of Adaptive Biotechnologies at 4.07 subject to Rule 16b-3
 
Griffin Michelle Renee over two weeks ago
Disposition of 15664 shares by Griffin Michelle Renee of Adaptive Biotechnologies at 7.94 subject to Rule 16b-3
 
Griffin Michelle Renee over three weeks ago
Acquisition by Griffin Michelle Renee of 23726 shares of Adaptive Biotechnologies at 8.12 subject to Rule 16b-3
 
Francis Lo over three weeks ago
Disposition of 13790 shares by Francis Lo of Adaptive Biotechnologies at 6.99 subject to Rule 16b-3
 
Robins Chad M over a month ago
Disposition of 211160 shares by Robins Chad M of Adaptive Biotechnologies at 6.32 subject to Rule 16b-3
 
Kyle Piskel over three months ago
Disposition of 248 shares by Kyle Piskel of Adaptive Biotechnologies at 4.98 subject to Rule 16b-3
 
Susan Bobulsky over three months ago
Disposition of 5000 shares by Susan Bobulsky of Adaptive Biotechnologies at 1.98 subject to Rule 16b-3
 
Stacy Taylor over six months ago
Acquisition by Stacy Taylor of 990 shares of Adaptive Biotechnologies subject to Rule 16b-3

Adaptive Biotechnologies Outstanding Bonds

Adaptive Biotechnologies issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Adaptive Biotechnologies uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Adaptive bonds can be classified according to their maturity, which is the date when Adaptive Biotechnologies Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Adaptive Biotechnologies Predictive Daily Indicators

Adaptive Biotechnologies intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Adaptive Biotechnologies stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Adaptive Biotechnologies Corporate Filings

F4
26th of March 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
17th of March 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
12th of March 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
6th of March 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
10K
3rd of March 2025
Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance
ViewVerify
F4
21st of February 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
18th of February 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
14th of February 2025
Other Reports
ViewVerify

Adaptive Biotechnologies Forecast Models

Adaptive Biotechnologies' time-series forecasting models are one of many Adaptive Biotechnologies' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Adaptive Biotechnologies' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Adaptive Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Adaptive Biotechnologies prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Adaptive shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Adaptive Biotechnologies. By using and applying Adaptive Stock analysis, traders can create a robust methodology for identifying Adaptive entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(0.89)(0.94)
Operating Profit Margin(0.91)(0.95)
Net Loss(0.89)(0.94)
Gross Profit Margin 0.60  0.73 

Current Adaptive Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Adaptive analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Adaptive analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
7.58Strong Buy8Odds
Adaptive Biotechnologies Corp current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Adaptive analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Adaptive stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Adaptive Biotechnologies, talking to its executives and customers, or listening to Adaptive conference calls.
Adaptive Analyst Advice Details

Adaptive Stock Analysis Indicators

Adaptive Biotechnologies Corp stock analysis indicators help investors evaluate how Adaptive Biotechnologies stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Adaptive Biotechnologies shares will generate the highest return on investment. By understating and applying Adaptive Biotechnologies stock analysis, traders can identify Adaptive Biotechnologies position entry and exit signals to maximize returns.
Begin Period Cash Flow68 M
Common Stock Shares Outstanding147.1 M
Total Stockholder Equity202.7 M
Property Plant And Equipment Net94.4 M
Cash And Short Term Investments222.3 M
Cash47.9 M
Accounts Payable7.3 M
Net Debt41.5 M
50 Day M A7.8128
Total Current Liabilities98.1 M
Other Operating Expenses341.5 M
Non Current Assets Total255.6 M
Non Currrent Assets Other38.8 M
Stock Based Compensation53.6 M

Additional Tools for Adaptive Stock Analysis

When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.